Capital Fund Management (CFM)
AKRO

Capital Fund Management (CFM)’s Akero Therapeutics AKRO Stock Holding History

Capital Fund Management (CFM)’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-17,619
Closed -$413K – 1950
2024
Q2 		$413K Sell
17,619
-3,704
-17% -$79.2K ﹤0.01% 1787
2024
Q1 		$539K Sell
21,323
-1,896
-8% -$45.5K ﹤0.01% 1850
2023
Q4 		$542K Buy
+23,219
New +$458K ﹤0.01% 1975
2023
Q2 		– Sell
-15,231
Closed -$583K – 1653
2023
Q1 		$583K Buy
+15,231
New +$679K ﹤0.01% 1421

Other funds holding AKRO

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Capital Fund Management (CFM)'s AKRO Position: Q3 2024 in Review

Capital Fund Management (CFM) sold out of Akero Therapeutics (AKRO) in Q3 2024, closing a stake of 17,619 shares — an estimated $413K sold.

Capital Fund Management (CFM) first reported a position in AKRO in Q1 2023 and held it in 4 quarters. The position peaked at $583K in Q1 2023. 168 funds tracked by Wall St. Rank hold AKRO as of Q3 2024.

  • Capital Fund Management (CFM) reported no remaining Akero Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Capital Fund Management (CFM) sold 17,619 Akero Therapeutics shares in Q3 2024, an estimated $413K.
  • Capital Fund Management (CFM) first reported a position in Akero Therapeutics in Q1 2023 and held it in 4 quarters.
  • Capital Fund Management (CFM)'s Akero Therapeutics position peaked at $583K in Q1 2023.
  • 168 funds tracked by Wall St. Rank held Akero Therapeutics as of Q3 2024.

Based on Capital Fund Management (CFM)'s 13F filing for Q3 2024, filed 13 Nov 2024.